Lassen Therapeutics

Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva's platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.

RayzeBio Inc is a San Diego-based biotechnology company that specializes in the development of innovative therapies for various types of cancer, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), small cell lung cancer (ES-SCLC), and hepatocellular carcinoma. With a strong focus on discovery and manufacturing capabilities, RayzeBio is committed to advancing its pipeline of potential treatments through rigorous research and development. The company's dedicated team of professionals, along with its collaborations with investors and partners, contribute to its mission of making a significant impact in the field of oncology. RayzeBio Inc's corporate overview highlights its commitment to delivering cutting-edge solutions in cancer treatment. Through its participation in news events, presentations, and the release of relevant information, the company aims to keep stakeholders informed about its progress. With a focus on corporate governance and financial transparency, RayzeBio strives to provide a comprehensive understanding of its operations and performance. By leveraging its expertise and resources, RayzeBio aims to address critical unmet needs in cancer therapy and improve patient outcomes.Generated from the website

Adcentrx Therapeutics is a clinical-stage biotechnology company based in San Diego, California, dedicated to accelerating breakthroughs in developing protein conjugate therapeutics for cancer and other life-threatening diseases. The company aims to enhance patient treatment options by merging the targeting precision of biologics with the disease-fighting capabilities of small molecule payloads. With a focus on next-generation targeted therapies, Adcentrx Therapeutics is committed to improving outcomes for patients through innovative scientific approaches. The company has recently received Fast Track designation for its ADC therapy, ADRX0706, aimed at treating advanced cervical cancer. Generated from the website